Allergy

AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.

AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.

AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.

AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.

AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.

The OUtMATCH trial showed that individuals as young as age 1 year could tolerate small amounts of peanut and other allergens without an allergic reaction.

Budesonide oral suspension is the first oral therapy for EoE and represents a needed option in the category, offering flexibility for both patients and clinicians.

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

For patients with chronic sinusitis, disease exacerbations often require use of antibiotics and steroids, in addition to medical office visits, all of which impact quality of life.

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

Another new COVID-19 vaccine, the first and only once-daily amphetamine transdermal patch approved for the treatment of ADHD, and 5 more.

Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.

Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.

Adults with atopic disease and asthma had a 38% decreased risk of COVID-19 infection, according to a new UK study.

From obesity to pneumococcal disease, we have picked the top 6 FDA-approved drugs every primary care physician should know about from the second quarter.

The Asthma and Allergy Foundation of America recently released its annual Allergy Capitals™ report. Which cities are most challenging for patients with seasonal allergies?

Treatment for severe asthma may be enhanced using an online decision support tool that draws on expert treatment decisions for a wide variety of potential patient scenarios.

Dupilumab therapy for 4 weeks in adults with severe atopic dermatitis resulted in significant improvements in clinical outcomes with no adverse events reported.

The first and only drug to treat peanut allergy recently received approval, giving the growing number of patients a new treatment option.

Sample: The hygiene hypothesis states that early exposure to germs reduces the immune system’s ability to resist infections in later years. True or false?

How do we combat waning human immunity? Our slide show summarizes 5 new reports that suggest it’s essential to figure that out.